THIRD QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS (GlobeNewswire) - Nov 6, 2025 - "Continued to execute operational steps necessary for the initiation of the Phase 2 MOMENTUM trial of cemsidomide in combination with dexamethasone in the fourth line or later for the first quarter of 2026 and the Phase 1b trial of cemsidomide in combination with elranatamab in the second line or later for the second quarter of 2026."
New P1 trial • New P2 trial • Multiple Myeloma
|